Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux

Paediatric Urinary Tract Infections and Vesicoureteral Reflux

Urinary tract infections (UTIs) represent one of the most common and clinically consequential bacterial infections in childhood, affecting approximately 2% of boys and 8% of girls by seven years of age. In infants and young children, acute pyelonephritis carries a distinct risk of permanent renal parenchymal scarring, which may predispose to long-term sequelae including hypertension, proteinuria, and chronic kidney disease (reflux nephropathy). Paediatricians must master the diagnostic nuances of sample collection, age-specific clinical manifestations, rational antibiotic stewardship, and risk-stratified radiological algorithms under European and international guidelines.

---

Pathogenesis and Microbiology

The vast majority of paediatric UTIs result from ascending infection, wherein enteric organisms colonize the periurethral mucosa and ascend retrogradely through the urethra into the bladder (cystitis) and potentially through the ureters into the renal pelvicalyceal system and parenchyma (acute pyelonephritis).

Primary Uropathogens

• Uropathogenic Escherichia coli (UPEC): Accounts for 75% to 90% of all community-acquired paediatric UTIs. UPEC strains possess specialized virulence factors:
  • P-fimbriae (pyelonephritis-associated pili): Bind specifically to glycosphingolipid receptors on uroepithelial cells, facilitating ascension against urinary flow and adherence to renal tubular epithelium.
  • Type 1 fimbriae: Mediate attachment to mannosylated uroplakin proteins in the bladder epithelium.
  • Hemolysin and Cytotoxic Necrotizing Factor 1 (CNF-1): Cause direct epithelial cytotoxicity and tissue invasion.
• Other Enterobacteriaceae (10–15%):
  • Klebsiella pneumoniae and Enterobacter species: Frequent in neonates, hospitalized infants, and children with anatomical anomalies.
  • Proteus mirabilis: Produces urease, which hydrolyzes urea into ammonia and carbon dioxide, raising urinary pH ($>7.5$) and precipitating magnesium ammonium phosphate (struvite stones). Common in uncircumcised boys.
  • Citrobacter and Serratia species: Associated with instrumentation and broad-spectrum antibiotic exposure.
• Gram-Positive Organisms (5%):
  • Enterococcus faecalis: Encountered in neonates, children with neurogenic bladder, or structural uropathies.
  • Staphylococcus saprophyticus: Important cause of uncomplicated cystitis in sexually active adolescent females.
  • Group B Streptococcus (Streptococcus agalactiae): Significant cause of early-onset neonatal sepsis and UTI.
• Pseudomonas aeruginosa: Highly virulent opportunistic pathogen observed in children with neurogenic bladder, indwelling urinary catheters, or reconstructive urinary tract surgery.

Host Defense Mechanisms and Predisposing Factors

Under normal physiological conditions, the urinary tract is protected by:

• Unidirectional, laminar urinary flow and periodic, complete bladder emptying.
• Tamm-Horsfall glycoprotein (uromodulin): Secreted by the thick ascending limb of Henle, binding to bacterial fimbriae and facilitating their clearance.
• Uroepithelial secretion of antimicrobial peptides (defensins, cathelicidins) and secretory IgA.

Predisposing risk factors for paediatric UTI include:

• Bladder and Bowel Dysfunction (BBD): Chronic functional constipation with fecal impaction compresses the bladder neck, leading to incomplete voiding, urinary stasis, and high post-void residuals.
• Uncircumcised Infant Males: In the first six months of life, uncircumcised boys have a four- to eight-fold higher risk of UTI compared to circumcised males due to dense colonization of the preputial space by uropathogens.
• Congenital Anomalies of the Kidney and Urinary Tract (CAKUT): Posterior urethral valves (PUV), pelviureteric junction obstruction (PUJO), duplex collecting systems, and vesicoureteral reflux (VUR).
• Neurogenic Bladder: Spina bifida / myelomeningocele resulting in detrusor-sphincter dyssynergia and elevated intravesical storage pressures.

---

Age-Stratified Clinical Manifestations

The clinical presentation of paediatric UTI varies inversely with the patient's age. The younger the infant, the more non-specific and constitutional the symptoms.

---

Urine Collection Methodologies

Obtaining an uncontaminated urine specimen is the single most critical step in evaluating suspected paediatric UTI. Contamination with perineal, preputial, or fecal flora frequently leads to overdiagnosis, unnecessary hospitalizations, and redundant invasive imaging.

Non-Invasive Techniques

• Clean-Catch (Midstream) Urine:
  • The preferred non-invasive technique in both toilet-trained children and cooperative infants.
  • Procedure in infants: The perineum is cleaned with sterile water. The infant is placed un-nappied on a caregiver's lap. The "Quick-Wee" method (gentle suprapubic cutaneous stimulation with cold-fluid-soaked gauze for 5-minute cycles) significantly accelerates voiding. The midstream flow is captured directly into a sterile container without contacting the skin.
• Urine Collection Pads:
  • An absorbent pad is placed within a clean disposable nappy. The pad is inspected every 10 to 15 minutes. Once wet, urine is aspirated from the pad using a sterile syringe.
  • Acceptable alternative to clean catch, but carries a higher contamination risk if left in place prolonged or contaminated with stool.
• Adhesive Perineal Collection Bags (Bag Urine):
  • A plastic bag adhered to the perineum. Carries an unacceptably high false-positive culture rate of 50% to 70% due to skin commensals.
  • Interpretation: A positive bag culture cannot confirm UTI; obtain a reliable sample for culture. Negative dipstick screening lowers probability but does not exclude UTI in very young or high-risk infants. Treatment of serious illness must not wait for an unobtainable sample.

Invasive Techniques

• Urethral Catheterization:
  • Indicated in acutely unwell, toxic, or hemodynamically unstable infants requiring immediate antimicrobial therapy when clean catch cannot be obtained promptly.
  • Performed using sterile technique with a 6-Fr or 8-Fr feeding tube/catheter.
• Suprapubic Aspiration (SPA):
  • The ultimate reference "gold standard" for obtaining pristine bladder urine in neonates and young infants.
  • Performed with a 21- to 23-gauge needle attached to a syringe, inserted 1 to 2 cm superior to the pubic symphysis in the midline at a 90-degree angle.
  • Bedside ultrasound guidance should always be utilized to confirm adequate bladder volume prior to puncture, increasing success rates to >90% and preventing dry taps or visceral injury.

                         [Suspected Paediatric UTI]
                                     |
       [Reliable urine sample before antibiotics where possible]
       [Do not delay urgent treatment if sampling is impractical]
                                     |
            +------------------------+------------------------+
            |                                                 |
   [Under 3 months or high-risk]                   [Age >=3 months, clinically stable]
   [Upper UTI/serious illness]                                |
            |                                      [Clean catch; pad if needed]
   [Urgent microscopy/culture]                      [Catheter/SPA if impractical]
   [Paediatric assessment]                                    |
            |                                 +--------------+---------------+
   [Catheter/SPA if required]                   |                              |
                                       [Positive dipstick]           [Negative dipstick]
                                       [Culture/treat by age]         [UTI less likely]
                                                                     [Culture if recurrent,
                                                                      persistent or discordant]

---

Urinalysis and Diagnostic Thresholds

Rapid dipstick urinalysis guides initial care. Infants under 3 months require urgent microscopy/culture. At 3 months to under 3 years, either LE or nitrite positivity warrants culture and antibiotics. The table below applies from 3 years; culture despite a negative dipstick if upper UTI, serious illness, recurrence, persistence or clinical discordance is present.

Urinalysis Parameter Interpretation

• Leukocyte Esterase (LE):
  • Marker of pyuria. Detects esterase released from broken down or intact polymorphonuclear leukocytes.
  • Sensitivity: 80% to 90%; Specificity: 70% to 85%.
  • False positives: Vaginal discharge, balanitis, extreme dehydration, kawasaki disease, interstitial nephritis.
  • False negatives: High specific gravity, glucosuria, presence of cephalosporins, or early infection.
• Nitrite Test:
  • Detects the conversion of dietary nitrate into nitrite by bacterial nitrate reductase, an enzyme present in most Gram-negative enteric bacilli (E. coli, Klebsiella, Proteus).
  • Specificity: 98% (a positive test is virtually diagnostic of bacteriuria); Sensitivity: 45% to 60%.
  • Causes of False-Negative Nitrite:
    • Frequent infant voiding: Bacteria require at least 4 hours of bladder dwell time to convert nitrate into measurable quantities of nitrite. Infants who void hourly will frequently test nitrite-negative despite high-titer E. coli pyelonephritis.
    • Infection caused by non-nitrate-reducing organisms: Enterococcus faecalis, Pseudomonas aeruginosa, Staphylococcus saprophyticus, or Candida.
    • Low dietary intake of vegetables (nitrates).

Microbiological Diagnostic Criteria

Quantitative urine culture remains the definitive diagnostic gold standard. The diagnostic colony count threshold depends strictly on the collection method:

• Clean-Catch Midstream Specimen: Pure growth of $\ge 10^5\text{ colony-forming units (CFU)/mL}$ ($10^8\text{ CFU/L}$) of a single uropathogen.
• Urethral Catheterization: Pure growth of $\ge 10^4\text{ CFU/mL}$ (or $10^4\text{--}10^5\text{ CFU/mL}$ in symptomatic patients).
• Suprapubic Aspiration (SPA): Any growth of a pathogenic organism is significant; interpret it with the clinical presentation and urinalysis.
• Mixed Growth: The presence of two or more distinct bacterial organisms almost invariably represents perineal or fecal contamination and warrants re-sampling.

---

Evidence-Based Antimicrobial Therapy

Therapeutic decisions are guided by the clinical differentiation between upper UTI (acute pyelonephritis) and lower UTI (cystitis), the child's age, and the presence of systemic toxicity.

Acute Pyelonephritis / Febrile UTI

• Indications for Intravenous (IV) Therapy:
  • Neonates and infants younger than 2 to 3 months of age.
  • Toxic, septic, or hemodynamically compromised appearance.
  • Intractable vomiting, severe dehydration, or inability to retain oral medications.
  • Known severe renal tract anomaly, neurogenic bladder, or renal impairment.
  • Social concerns or uncertainty regarding treatment compliance.
• Empiric Intravenous Regimens:
  • Infants $\ge 2\text{--}3$ months: IV Ceftriaxone (50 to 75 mg/kg once daily) or IV Cefotaxime (150 mg/kg/day divided 8-hourly).
  • Neonates (<2 months): IV Ampicillin (to cover Enterococcus and Listeria) plus IV Gentamicin (or Cefotaxime). When using gentamicin, therapeutic drug monitoring of peak and trough levels is mandatory to prevent nephrotoxicity and ototoxicity.
  • Alternative (penicillin allergy): IV Ciprofloxacin or Aminoglycoside.
• Oral Switch and Total Duration:
  • Transition to oral antibiotics is indicated once the child is clinically afebrile for 24 to 48 hours, feeding well, and antimicrobial sensitivities are confirmed.
  • Total antibiotic duration for acute pyelonephritis: 7 to 10 days (up to 14 days in neonates or complicated cases).

Uncomplicated Lower UTI (Cystitis) / Mild Febrile UTI

• Children older than 2 to 3 months with mild symptoms, no systemic toxicity, and normal oral fluid intake can be treated entirely with oral antibiotics.
• Empiric Oral Options:
  • Cefalexin: 50 mg/kg/day divided 8-hourly.
  • Amoxicillin-Clavulanic Acid (Co-amoxiclav): 30 to 50 mg/kg/day divided 8-hourly.
  • Trimethoprim-Sulfamethoxazole (Co-trimoxazole): 6 to 8 mg/kg/day of trimethoprim component divided 12-hourly.
• Total Duration for Cystitis: 3 to 5 days.

---

Post-UTI Imaging: NICE and EAU Approaches

Radiological imaging post-UTI aims to identify treatable structural uropathies (such as posterior urethral valves), detect vesicoureteral reflux (VUR), and evaluate renal cortical scarring, while minimizing radiation exposure and procedural trauma.

Definitions of Complex UTI Subtypes

• Atypical UTI: A UTI featuring any of the following:
  • Severe systemic illness, sepsis, or septic shock
  • Poor urine flow or abnormal urinary stream (suggestive of posterior urethral valves in boys)
  • Palpable abdominal, renal, or suprapubic mass
  • Raised serum creatinine or electrolyte disturbance
  • Failure to respond clinically (persistent fever or positive repeat culture) within 48 hours of starting appropriate antibiotics
  • Infection caused by a non-E. coli organism (Proteus, Pseudomonas, Enterobacter, Klebsiella)
• Recurrent UTI:
  • Two or more episodes of acute pyelonephritis / upper UTI, OR
  • One episode of upper UTI plus one or more episodes of lower UTI, OR
  • Three or more episodes of lower UTI / cystitis.

Core Imaging Modalities

1. Renal and Bladder Ultrasound (RBUS):
   • Non-invasive, radiation-free evaluation of renal size, parenchymal thickness, pelvicalyceal dilatation, ureteric dilatation, bladder wall thickening, and post-void residual volume.
   • Acute RBUS under NICE: Indicated during atypical UTI and for recurrent UTI in infants under 6 months, to detect obstruction and other abnormalities. A responding non-E. coli infection with no other atypical feature may have ultrasound within 6 weeks.
   • Elective RBUS (within 6 weeks): Indicated in infants younger than 6 months responding well to treatment for their first febrile UTI.
2. DMSA Scintigraphy ($^{99m}\text{Tc}$-Dimercaptosuccinic Acid):
   • The diagnostic gold standard for evaluating renal parenchymal integrity and permanent cortical scarring.
   • Technetium-labeled DMSA is actively taken up by proximal convoluted tubular cells and fixed within the renal cortex.
   • Acute Phase: Reveals focal areas of photopenia (decreased uptake) representing acute parenchymal ischemia and inflammation (acute pyelonephritis).
   • Chronic Phase: Must be performed at least 4 to 6 months after the acute infection to allow post-inflammatory parenchymal healing. Persistent photopenic wedge defects with volume loss and cortical thinning define permanent renal scarring.
3. Micturating Cystourethrogram (MCUG / VCUG):
   • The gold standard for detecting and grading Vesicoureteral Reflux (VUR) and visualizing the male urethra to diagnose Posterior Urethral Valves (PUV).
   • Involves sterile urethral catheterization, instillation of radio-opaque contrast until maximum bladder filling, and continuous fluoroscopy during active voiding.
   • NICE indications: MCUG is recommended for atypical or recurrent UTI under 6 months; consider it after an abnormal ultrasound. From 6 months to under 3 years, do not perform MCUG routinely, but consider it with dilatation, poor flow, non-E. coli infection or family history of VUR. It is not routine from age 3 years.

For a responding non-E. coli infection without other atypical features, NICE permits ultrasound within 6 weeks rather than acutely. EAU differs: it recommends RBUS for febrile UTI, within 24 hours in infants/acutely ill children, with later imaging possible in stable outpatients. Consider VCUG after febrile UTI below 1 year, atypical/recurrent infection or abnormal ultrasound; consider DMSA at least 6 months after febrile UTI for scarring assessment.

---

Vesicoureteral Reflux (VUR)

Vesicoureteral reflux is the retrograde passage of urine from the bladder into the upper urinary tract through an incompetent ureterovesical junction (UVJ).

Pathophysiology

In healthy individuals, the ureter traverses the bladder wall obliquely through an intramural tunnel within the detrusor muscle before opening at the trigone. As the bladder fills and detrusor pressure rises, the intramural ureter is compressed against the bladder wall, creating a passive one-way flap-valve mechanism that prevents retrograde flow.

• Primary VUR: Congenital shortening of the intramural ureteric tunnel (subnormal tunnel-to-diameter ratio, normally 5:1). Tendency toward spontaneous resolution as the child grows and the intramural tunnel elongates.
• Secondary VUR: Elevated intravesical pressures that overcome a normal valve mechanism, resulting from posterior urethral valves, neurogenic bladder, or severe bladder-bowel dysfunction.

International Reflux Study Classification (Grades I to V)

   Grade I        Grade II        Grade III         Grade IV          Grade V

      |              |                (                ((              (((  
      |              |               (  )             ((  ))          (((   )))
      |              |              (    )           ((    ))        (((     )))
      |              |              |    |           |      |        |         |
      |              |              |    |           |      |        |         |
      |              |              /    \           /      \       (           )
      |              |             /      \         /        \     (             )
   Ureter         Pelvis/       Mild dilation   Moderate dilation  Severe tortuosity
    only          calyces,       & blunting of   & tortuosity of    & loss of papillary
                 no dilation        fornices         ureter            impressions

• Grade I: Reflux into non-dilated ureter only; does not reach the renal pelvis.
• Grade II: Reflux reaches the renal pelvis and calyces without dilatation; calyceal fornices remain sharp and normal.
• Grade III: Mild-to-moderate dilatation and tortuosity of the ureter and renal pelvis; mild blunting of calyceal fornices.
• Grade IV: Moderate dilatation and tortuosity of the ureter and pelvis; complete blunting of calyces with preservation of papillary impressions.
• Grade V: Severe dilatation and tortuosity of the ureter and renal pelvis; loss of calyceal papillary impressions; intrarenal reflux may be seen. Renal scarring is assessed separately.

Management Strategies for VUR

1. Conservative Medical Surveillance:
   • EAU estimates spontaneous resolution in nearly 80% of grades I–II and 30–50% of grades III–V within 4–5 years; bilateral high-grade reflux resolves less often.
   • Routine aggressive treatment of associated bladder-bowel dysfunction (BBD) with bowel laxatives (macrogol / polyethylene glycol), timed voiding (every 2–3 hours), and double voiding techniques.
2. Continuous Antibiotic Prophylaxis (CAP):
   • Low-dose bedtime antibiotic (e.g., Trimethoprim 2 mg/kg nightly, or Nitrofurantoin 1–2 mg/kg nightly for infants $>3$ months).
   • Indicated primarily in infants with high-grade VUR (Grades IV and V) or children with recurrent febrile UTIs, to reduce recurrent febrile UTIs; prevention of new renal scarring has not been established.
3. Interventional Therapy (Endoscopic and Surgical):
   • Indications: Breakthrough febrile UTIs despite CAP, persistent high-grade VUR (Grades IV–V) after 2 to 3 years of surveillance, or evidence of progressive new cortical scarring on DMSA.
   • Endoscopic Subureteric Transurethral Injection (STING): Injection of a biocompatible bulking agent (dextranomer/hyaluronic acid copolymer, Deflux) beneath the ureteric orifice to coapt the intramural lumen. Minimally invasive day-case procedure with $>80\%$ success.
   • Ureteric Reimplantation (Cohen Cross-Trigonal / Politano-Leadbetter): Open or robotic-assisted surgical mobilization of the ureter with surgical reconstruction of an elongated intramural tunnel; definitive cure rate $>95\%$.

---

Enuresis: Bedwetting and Daytime Wetting

• Children are usually expected to be dry at night by a developmental age of about 5 years. Bedwetting is secondary if it starts after at least 6 months of dryness.
• Tell the child and family that bedwetting is not the child's fault and that punishment must not be used.
• Assess the pattern, daytime symptoms (frequency, urgency, daytime wetting, straining or a poor stream), fluid intake and toileting, and look for constipation, diabetes mellitus, urinary tract infection, developmental or emotional problems and family stress. Urinalysis is not routine but is needed if bedwetting is recent, if there are daytime symptoms or signs of illness, or if UTI or diabetes is suspected. Persistent secondary wetting without a medical explanation, or punishment for wetting despite advice, should raise concern about maltreatment.
• First steps: adequate daytime drinks, avoiding caffeine, regular voiding during the day and before sleep, and rewards for agreed behaviours rather than for dry nights.
• Enuresis alarm: first-line treatment for motivated families. Review at 4 weeks and continue until at least 2 weeks of uninterrupted dry nights.
• Desmopressin: used when rapid or short-term dryness is the priority or an alarm is unsuitable, mainly from 7 years and considered from 5 years. Restrict fluid from 1 hour before until 8 hours after each dose because of the risk of water intoxication and hyponatraemia. Review at 4 weeks and continue for 3 months if responding. It is not used for daytime wetting alone.
• Investigate and treat daytime symptoms first when they predominate, and refer when bedwetting does not respond to treatment or when bladder or neurological disease is suspected.

Source: NICE CG111 Bedwetting in under 19s.